Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Merck’s Head Of Global Clinical Development & Chief Medical Officer Dr. Roy D. Baynes Announces Retirement – $MRK $DIA

By John F. Heerdink, Jr.

As per reports, the head of Global Clinical Development (GCD), and Chief Medical Officer, Merck Research Laboratories (MRL) (MRK) , Dr. Roy D. Baynes announces retirement from the position in July. He will be succeeded by Dr. Eliav Barr, effective April 1, 2022. Dr. Baynes will continue to report to Dr. Dean Y. Li, president, of Merck Research Laboratories, until his retirement.

Dr. Baynes joined Merck in 2013, and under his leadership, Merck has become a leading oncology company and achieved more than 140 medicine and vaccine approvals globally across numerous therapeutic areas.

Dr. Baynes stated, “It has been a privilege to have led the global clinical development organization during my tenure at Merck. I am immensely proud of the team’s accomplishments and the difference we are making in the lives of patients worldwide. I look forward to continuing to work with Eliav in the coming months to ensure a smooth transition.”

Dr. Barr is a cardiologist by training, prior to joining Merck in 1995 he held a faculty position at the University of Chicago. He completed his undergraduate degree from Penn State University and his medical degree from Sidney Kimmel Medical College, Thomas Jefferson University. He holds his Internal Medicine residency and Cardiology Fellowship from Johns Hopkins University and subsequently pursued post-doctoral training at the University of Michigan.

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

(Read Original Story: Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer in Business Wire)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us